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ABSTRACT Vitamin D [1,25(OH)2D3] plays a crucial
role in Ca2 homeostasis by stimulating Ca2 (re)ab-
sorption and bone turnover. The 1,25(OH)2D3 analog
ZK191784 was recently developed to dissociate the
therapeutic immunomodulatory activity from the hy-
percalcemic side effects of 1,25(OH)2D3 and contains a
structurally modified side chain characterized by a
22,23-double bond, 24R-hydroxy group, 25-cyclopropyl
ring, and 5-butyloxazole unit. We investigated the effect
of ZK191784 on Ca2 homeostasis and the regulation
of Ca2 transport proteins in wild-type (WT) mice and
mice lacking the renal epithelial Ca2 channel TRPV5
(TRPV5/). The latter display hypercalciuria, hyper-
vitaminosis D, increased intestinal expression of the
epithelial Ca2 channel TRPV6, the Ca2-binding pro-
tein calbindin-D9K, and intestinal Ca
2 hyperabsorp-
tion. ZK191784 normalized the Ca2 hyperabsorption
and the expression of intestinal Ca2 transport pro-
teins in TRPV5/ mice. Furthermore, the compound
decreased intestinal Ca2 absorption in WT mice and
reduced 1,25(OH)2D3-dependent
45Ca2 uptake by
Caco-2 cells, substantiating a 1,25(OH)2D3-antagonistic
action of ZK191784 in the intestine. ZK191784 in-
creased renal TRPV5 and calbindin-D28K expression
and decreased urine Ca2 excretion in WT mice. Both
1,25(OH)2D3 and ZK191784 enhanced transcellular
Ca2 transport in primary cultures of rabbit connecting
tubules and cortical collecting ducts, indicating a
1,25(OH)2D3-agonistic effect in kidney. ZK191784 en-
hanced bone TRPV6 mRNA levels and 1,25(OH)2D3 as
well as ZK191784 stimulated secretion of the bone
formation marker osteocalcin in rat osteosarcoma
cells, albeit to a different extent. In conclusion,
ZK191784 is a synthetic 1,25(OH)2D3 ligand display-
ing a unique tissue-specific profile when adminis-
tered in vivo. Because ZK191784 acts as an intestine-
specific 1,25(OH)2D3 antagonist, this compound will
be associated with less hypercalcemic side effects
compared with the 1,25(OH)2D3 analogs currently
used in clinical practice.—Nijenhuis, T., van der
Eerden, B. C. J., Zu¨gel, U., Steinmeyer, A., Weinans,
H., Hoenderop, J. G. J., van Leeuwen, J. P. T. M.,
Bindels, R. J. M. The novel vitamin D analog
ZK191784 as an intestine-specific vitamin D antago-
nist. FASEB J. 20, E1589–E1598 (2006)
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The main physiological function of the active form
of vitamin D [1,25(OH)2D3] is to stimulate intestinal
and renal Ca2 (re)absorption and regulate bone Ca2
turnover (1, 2). In addition, 1,25(OH)2D3 has potent
antiproliferative, immunosuppressive, and immuno-
modulatory activity (3–5). However, therapeutic admin-
istration of 1,25(OH)2D3 frequently has dose-limiting
hypercalcemic side effects, increasing the risk of soft-
tissue and vascular calcification as well as osteoporosis
when administered in a supraphysiological dose (6, 7).
Therefore, there has been great effort in identifying
new 1,25(OH)2D3 analogs that retain a beneficial ther-
apeutic profile combined with minimal calcemic ac-
tion. Such analogs would have attractive clinical poten-
tial as immunomodulators in hyperproliferative
disorders or to treat secondary hyperparathyroidism
complicating chronic kidney disease (8).
The 1,25(OH)2D3 analog ZK191784 was developed
in an effort to dissociate the immunomodulatory and
hypercalcemic actions of 1,25(OH)2D3 (3). This com-
pound contains a structurally modified side chain char-
acterized by a 22,23-double bond, 24R-hydroxy group,
25-cyclopropyl ring, and 5-butyloxazole unit (Fig. 1).
ZK191784 competitively binds to the vitamin D recep-
tor (VDR) with a similar affinity as 1,25(OH)2D3 (3).
Like 1,25(OH)2D3, ZK191784 inhibited antigen-in-
duced lymphocyte proliferation and cytokine secretion
in vitro and exhibited potent immunosuppressive activ-
ity in a murine model of contact hypersensitivity. In
addition, it exerted a 1,25(OH)2D3-antagonistic effect
on the promyelocytic leukemia cell line HL-60. This
latter cell model is often used to study the genomic
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responses of 1,25(OH)2D3 analogs (3, 9), and antago-
nism of HL-60 differentiation was previously shown
with several vitamin D analogs that have 1,25(OH)2D3-
antagonistic profiles in vivo (10–13). However, the in
vivo effects of ZK191784 regarding Ca2 homeostasis
and regulation of the Ca2 transport proteins have not
been evaluated in detail.
1,25(OH)2D3-stimulated transcellular Ca
2 (re)ab-
sorption involves Ca2 entry across the luminal mem-
brane via the epithelial Ca2 channels TRPV5 and
TRPV6 (1, 14–16). TRPV5 is localized at the luminal
membrane of the late distal convoluted tubule (DCT)
and connecting tubule (CNT) in kidney. TRPV6 is the
homologous epithelial Ca2 channel localized along
the brush-border membrane of the duodenum. After
Ca2 entry across the luminal membrane, Ca2 bound
to Ca2-binding proteins (calbindins) diffuse to the
basolateral membrane of the cell. Ca2 is finally ex-
truded to the blood compartment by the Na/Ca2
exchanger (NCX1) and/or the plasma membrane
Ca2-ATPase (PMCA1b). The stimulatory effect of
1,25(OH)2D3 on the expression of the epithelial Ca
2
channels in kidney and duodenum has been demon-
strated and is probably associated with its hypercalce-
mic side effects (1). Furthermore, recent studies
showed the expression of TRPV5 and TRPV6 in bone
and demonstrated that TRPV5 is exclusively expressed
in osteoclasts where it is involved in osteoclastic bone
resorption (17, 18).
TRPV5 knockout (TRPV5/) mice display pro-
found renal Ca2 wasting due to impaired active Ca2
reabsorption in DCT and CNT (19). Furthermore,
elevated serum 1,25(OH)2D3 levels, intestinal Ca
2
hyperabsorption, and reduced bone thickness were
demonstrated in these mice. We showed that additional
ablation of 25-hydroxyvitamin-D3-1-hydroxylase (1-
OHase), the renal enzyme responsible for
1,25(OH)2D3 biosynthesis, decreased intestinal TRPV6
expression and Ca2 absorption in TRPV5//1-
OHase/ mice (20). Therefore, hypervitaminosis D in
these mice appears to represent a compensatory mech-
anism in an effort to counteract the significant renal
Ca2 leak. Thus, TRPV5/ mice constitute an ideal
animal model to study the effects of compounds with
possible 1,25(OH)2D3-antagonistic actions.
The aim of the present study was, therefore, to
evaluate the in vivo effect of the novel 1,25(OH)2D3
analog ZK191784 on Ca2 and bone homeostasis in WT
and TRPV5/ mice. Animals were treated with
ZK191784 for 28 days, after which Ca2 absorption,
Ca2 excretion,and expression of the Ca2 transport
proteins in intestine, kidney, and bone was determined.
In addition, bone morphometry was assessed by de-
tailed microcomputed tomographic analysis. Further
characterization of the actions of ZK191784 on intesti-
nal, renal, and osteoblast cell lines was performed to
reveal the biological profile of this novel 1,25(OH)2D3
analog.
MATERIALS AND METHODS
ZK191784 treatment in TRPV5/ (wild-type) and
TRPV5/ mice
TRPV5/ mice were generated by targeted ablation of the
TRPV5 gene (19). TRPV5/ (wild-type) mice and
TRPV5/ littermates were housed in a light and tempera-
ture-controlled room with ad libitum access to deionized
drinking water and standard pelleted chow (0.25% (wt/v) Na;
1.1% (wt/v) Ca). Ten-week-old TRPV5/ and TRPV5/
mice were treated during 28 days with 50 g/kg/day
ZK191784 [(5Z,7E,22E)-(1S,3R,24R)-25-(5-butyloxazole-2-yl)-
26,27-cyclo-9,10-secocholesta-5,7,10(19),22-tetraene-1,3,24-
triol; Schering AG, Berlin, Germany; Fig. 1; n9] or vehicle
(n9) by daily subcutaneous injection. This dose was based
on previous in vivo experiments using ZK191784 (3). Mice
were treated for 28 days, after which the animals were housed
in metabolic cages enabling ration feeding and collection of
24 h urine samples under mineral oil, preventing evapora-
tion. At the end of the experiment the animals were killed,
blood samples were taken, and duodenum, kidney, and
femur were sampled. The animal ethics board of the Rad-
boud University Nijmegen approved all animal studies.
Analytical procedures
Serum and urine Ca2 concentrations were determined using
a colorimetric assay as described previously (21, 22). Mouse
serum PTH was measured using an immunoradiometric assay
(Immutopics, San Clemente, CA). Na and Li concentra-
tions were determined flame-spectrophotometrically (Eppen-
dorf FCM 6343, Hamburg, Germany). Urine pH was mea-
sured using an electronic ion analyzer (Hanna Instruments,
Szeged, Hungary).
In vivo 45Ca2 absorption assay
Intestinal Ca2 absorption was assessed by measuring serum
45Ca2 at early time points after oral gavage. Mice were
treated for 28 days with 50 g/kg/day ZK191784 or vehicle as
described above and were fasted 12 h before the experiment.
Animals were hemodynamically stable under anesthesia dur-
ing the assay. The 45CaCl2 was administrated by oral gavage as
described previously (19). Blood samples were obtained at
indicated time intervals, and serum was analyzed by liquid
scintillation counting. The change in the plasma Ca2 con-
Figure 1. Chemical structure of 1,25(OH)2D3 and its analog
ZK191784. Compared with1,25(OH)2D3, ZK191784 contains
a structurally modified side chain characterized by a 22,23-
double bond, 24R-hydroxy group, 25-cyclopropyl ring and
5-butyloxazole unit.
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centration (M) was calculated from the 45Ca2 content of
the serum samples and the specific activity of the adminis-
tered Ca2.
Real-time quantitative polymerase chain reaction analysis
Total RNA was extracted from duodenum, kidney, and bone
using TriZol Total RNA Isolation Reagent (GIBCO, Breda,
the Netherlands). Femurs, from which the bone marrow was
removed by flushing with PBS, were first homogenized using
a Mikro Dismembrator S (Sartorius, Goettingen, Germany).
The obtained RNA was subjected to DNase treatment and
reverse transcribed (22). Subsequently, the cDNA was used to
determine TRPV6 and calbindin-D9K mRNA levels in duode-
num, TRPV5 and calbindin-D28K mRNA expression in kidney,
and TRPV5 and TRPV6 mRNA in bone by real-time quanti-
tative polymerase chain reaction (PCR) as described previ-
ously (22, 23). In addition, mRNA expression of the house-
keeping gene hypoxanthine-guanine phosphoribosyl
transferase (HPRT) was determined as an endogenous con-
trol, which enabled calculation of specific mRNA expression
levels as a ratio of HPRT. To determine the mRNA expression
level of TRPV6 in human osteoblast cultures, species-specific
primers and probes were used. For TRPV6, these were the
forward primer, 5-GCTTTGCTTCAGCCTTCTATATCAT-3;
reverse primer, 5-TGGTAAGGAACAGCTCGAAGGT-3 and
5-AGGAGCTAGGCCACTTCTACGACTAC CCCA-3 as
probe. In the case of the housekeeping gene GAPDH, these
were 5-ATGGGGAAGGTGAAGGTCG-3, 5-TAAAAGCAGC-
CCTGGTGACC-3, and 5-CGCC CAATACGACCAAATC-
CGTTGAC-3.
Immunohistochemistry
Staining of kidney sections for TRPV5 and calbindin-D28K was
performed on cryosections of periodate-lysine-paraformalde-
hyde fixed kidney samples as described previously (22, 23).
For semiquantitative determination of protein abundance,
images were made using a Zeiss fluorescence microscope
equipped with a digital camera (Nikon DXM1200). Images
were analyzed with the Image Pro Plus 4.1 image analysis
software (Media Cybernetics, Silver Spring, MD), resulting in
quantification of the protein levels as the mean of integrated
optical density (IOD).
Bone analysis
To evaluate the effects of ZK191784 on bone and the possible
correlation between epithelial Ca2 channel expression and
bone homeostasis, femurs from control and ZK191784-
treated TRPV5/ and TRPV5/ mice were scanned using
the SkyScan 1072 microtomograph (SkyScan, Antwerp, Bel-
gium; ref 19). Scans were processed, and a three-dimensional
morphometric analysis of the bone was performed, using the
3D-Calculator project free software (http://www.eur.nl/fgg/
orthopaedics/Downloads.html). Measured parameters were
expressed according to bone histomorphometry nomencla-
ture (24).
45Ca2 uptake assay in the intestinal Caco-2 cell line
We performed a 45Ca2 uptake assay in the human colon
cancer Caco-2 cell line, which displays duodenal characteris-
tics, to determine the effect of ZK191784 in an established
intestinal cell model. The 45Ca2 uptake assay was performed
as described previously (15). In short, confluent monolayers
of Caco-2 cells were incubated for 48 h in normal Dulbecco’s
modified Eagle’s medium (DMEM) culture medium (15) or
culture medium supplemented with 1  107 M 1,25(OH)2D3,
1  107 M ZK191784, or 1  107 M 1,25(OH)2D3 together
with 1  107 M ZK191784, respectively. Cells were washed
with Krebs-Henseleit buffer (KHB) and, subsequently, were
preincubated for 8 min in KHB or KHB supplemented with
10 M of the TRPV6 blocker ruthenium red (Fluka, St. Louis,
MO; ref 1). Thereafter, the preincubation buffer was ex-
changed for 45Ca2 uptake buffer, containing 0.1 mM CaCl2,
2 mM NaH2PO4, 10 M felodipine, 10 M verapamil, and 1
Ci 45CaCl2. After incubation for 8 min, cells were washed
three times with ice-cold stop buffer consisting of KHB
supplemented with 0.5 mM CaCl2 and 1.5 mM LaCl3. Cells
were lysed in 0.1% (wt/v) SDS, and radioactivity of the lysate
was measured using a liquid scintillation counter.
Transcellular Ca2 transport in rabbit kidney CNT and
CCD primary cell cultures
Rabbit kidney CNT and CCD tubules were immunodissected
from the kidney cortex of New Zealand White rabbits and
grown on permeable filters (Costar 0.33 cm2), as described in
detail previously (25). Filters containing confluent monolay-
ers of CNT and CCD cells were incubated with normal DMEM
culture medium (25) or culture medium supplemented with
1  107 M 1,25(OH)2D3, 1  10
7 M ZK191784, or 1  107 M
1,25(OH)2D3 together with 1  10
7 M ZK191784, respec-
tively. After 48 h of incubation, transepithelial Ca2 transport
was measured during 90 min as described previously.
Osteocalcin secretion in rat osteosarcoma cells
Osteocalcin is produced by mature postproliferative osteo-
blasts at the onset of extracellular matrix (ECM) production.
Ligand-induced osteocalcin production by reactive oxygen
species (ROS) 17/2.8 cells was used to assess the bone
formation potential of ZK191784. ROS 17/2.8 cells were
cultured in DMEM culture medium containing 5% (v/v)
charcoal treated fetal calf serum. Increasing concentrations
of 1,25(OH)2D3 and ZK191784 were applied for 72 h to
obtain a dose-response curve. Subsequently, the amount of
osteocalcin produced was measured.
Statistical analysis
Data are mean  se. Statistical comparisons were analyzed by
one-way ANOVA and Fisher’s multiple comparison. P values
	0.05 were considered statistically significant. All analyses
were performed using the StatView Statistical Package soft-
ware (Power PC version 4.51, Berkely, CA) on an Apple iMac
computer.
RESULTS
Metabolic studies in ZK191784-treated WT and
TRPV5/ mice
WT and TRPV5/ mice were treated for 28 days with
50 g/kg/day ZK191784 or vehicle by daily subcutane-
ous injection. The obtained metabolic data are shown
in Fig. 2 and Table 1. Genetic ablation of TRPV5
resulted in a 10-fold increase in Ca2 excretion com-
pared with WT mice (Fig. 2A). The in vivo 45Ca2
absorption measurements showed a profound enhance-
ment of intestinal Ca2 absorption in these TRPV5/
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mice (Fig. 2B). This was accompanied by a minor but
significant increase in the serum Ca2 concentration
(Table 1). ZK191784 treatment in TRPV5/ mice
normalized the intestinal Ca2 hyperabsorption as
well as the serum Ca2 concentration. In addition,
Ca2 excretion was decreased by ZK191784 adminis-
tration in TRPV5/ mice but remained significantly
elevated compared with WT mice (Fig. 2A). Further-
more, ZK191784 treatment significantly diminished
intestinal Ca2 absorption and decreased Ca2 ex-
cretion in WT mice, without altering serum Ca2
levels (Fig. 2B; Table 1). Urine volume, Na excre-
tion, and Li clearance were not affected by
ZK191784 in both TRPV5/ and TRPV5/ mice
(Table 1). Furthermore, serum PTH levels did not
significantly differ in the treated groups.
Duodenal mRNA expression of Ca2 transport
proteins
To study the effect of ZK191784 on the abundance of
Ca2 transporters in the intestine, TRPV6 and calbi-
ndin-D9K mRNA expression was determined by real-
time quantitative PCR analysis. TRPV5/ mice
showed profoundly increased TRPV6 (Fig. 3A) and
calbindin-D9K (Fig. 3B) mRNA levels in duodenum
compared with WT mice. Administration of
ZK191784 to TRPV5/ mice significantly reduced
the TRPV6 and calbindin-D9K mRNA abundance,
resulting in a complete normalization of the expres-
sion of the intestinal Ca2 transporters. ZK191784
treatment did not significantly alter TRPV6 and
calbindin-D9K mRNA levels in WT mice.
Figure 2. Renal Ca2 excretion and intestinal Ca2 absorp-
tion during treatment with ZK191784 in TRPV5/ and
TRPV5/ mice. Effect of ZK191784 on renal Ca2 excretion
was determined in metabolic cages (A). Intestinal Ca2
absorption was determined in an in vivo 45Ca2 absorption
assay, measuring serum 45Ca2 at early time points after oral
gavage (B). Controls, mice treated with vehicle only;
ZK191784, mice treated for 28 days with the 1,25(OH)2D3
analog ZK191784 (50 g/kg/day).   TRPV5/ controls,
treated with vehicle only; f  ZK191784-treated TRPV5/;
‚  TRPV5/ controls, treated with vehicle only; Œ 
ZK191784-treated TRPV5/. Data are mean  se. *P 	 0.05
vs. TRPV5/ controls; #P	 0.05 vs. TRPV5/ controls; n
9 animals per group.
TABLE 1. Serum and urine analysis during ZK191784 treatment in TRPV5/ and TRPV5/ mice
TRPV5/ TRPV5/
Controls ZK191784 Controls ZK191784
Serum
Ca2 (mm) 2.34  0.02 2.36  0.03 2.46  0.03* 2.35  0.03#
PTH (pg/ml) 11  1 16  5 24  6 24  11
Urine
Diuresis (ml/24 h) 2.7  0.1 2.1  0.3 5.4  0.3* 4.6  0.3
Na excretion (mmol/24 h) 0.1  0.1 0.1  0.1 0.5  0.1* 0.4  0.1
Li clearance (l/min) 14  1 11  2 16  2 13  1
Controls, mice treated with vehicle only; ZK191784, mice treated for 28 days with 1,25(OH)2D3 analog ZK191784 (50 g/kg/day). Data
are mean  se. *P 	 0.05 vs. TRPV5/ controls; #P 	 0.05 vs. TRPV5/ controls.
Figure 3. mRNA expression of duodenal Ca2 transporters
during treatment with ZK191784 in TRPV5/ and
TRPV5/ mice. The effect of ZK191784 treatment on
duodenal mRNA expression of the epithelial Ca2 channel
TRPV6 (A) and the cytosolic Ca2-binding protein cal-
bindin-D9K (CaBP9K; B) was determined by real-time quan-
titative PCR analysis and expressed as the ratio of HPRT
and depicted as percentage of TRPV5/ controls. Con-
trols, mice treated with vehicle only; ZK191784, mice
treated for 28 d with the 1,25(OH)2D3 analog ZK191784
(50 g/kg/day). Data are mean  se. *P 	 0.05 vs.
TRPV5/ controls; #P 	 0.05 vs. TRPV5/ controls; n 
9 animals per group.
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Renal expression of Ca2 transport proteins
To evaluate the effect of ZK191784 on the expression of
the Ca2 transport proteins in the kidney, TRPV5 and
calbindin-D28K mRNA, as well as protein abundance,
was determined by real-time quantitative PCR (Fig. 4)
and semiquantitative immunohistochemistry, respec-
tively (Fig. 5). ZK191784 significantly increased TRPV5
and calbindin-D28K mRNA levels and enhanced protein
abundance of these Ca2 transporters in DCT and CNT
of WT mice. In contrast, ZK191784 did not significantly
alter the reduced calbindin-D28K mRNA and protein
expression in TRPV5/ mice.
Expression of TRPV5 and TRPV6 mRNA in bone
Besides duodenum and kidney, bone is an important
tissue in Ca2 homeostasis and it was previously shown
that the epithelial Ca2 channels TRPV5 and TRPV6
are expressed in this tissue (18). Bone TRPV5 mRNA
levels as determined in femur were not affected by
ZK191784 in WT mice (Fig. 6A). TRPV5 gene ablation
did not alter the TRPV6 mRNA levels in femur (Fig.
6B). However, TRPV6 mRNA expression was signifi-
cantly enhanced in ZK191784-treated WT and
TRPV5/ mice.
Bone analysis
To evaluate the effects of ZK191784 on bone morphol-
ogy, femurs were scanned using microcomputed to-
mography (Fig. 7). Detailed three-dimensional mor-
phometric analysis demonstrated that trabecular
thickness (Tb.Th) is reduced in the femoral head of
TRPV5/ mice (Table 2). ZK191784 did not signifi-
cantly affect the bone morphometric parameters in the
femoral head of both mice strains. Analysis of the
metaphysis and diaphysis showed that cortical thickness
(Ct.Th) is also significantly reduced in TRPV5/ mice
compared with WT mice but is unaffected by ZK191784
treatment. There were no differences observed in the
other trabecular and cortical bone parameters between
the treated groups.
45Ca2 uptake assay in the intestinal Caco-2 cell line
To determine the effect of ZK191784 in an isolated
intestinal cell model, 45Ca2 uptake was determined in
the human Caco-2 cell line, which has duodenal char-
acteristics and expresses TRPV6 and calbindin-D9K (1,
26). Application of 1  107 M 1,25(OH)2D3 for 48 h
enhanced the ruthenium red-sensitive 45Ca2 uptake,
substantiating the presence of 1,25(OH)2D3-responsive
and TRPV6-mediated Ca2 absorption in these polar-
ized epithelial intestinal cells (Fig. 8A). In contrast,
incubation with 1  107 M ZK191784 did not stimulate
45Ca2 uptake. Importantly, concomitant application
of 1  107 M ZK191784 with 1  107 M 1,25(OH)2D3
significantly inhibited the 1,25(OH)2D3-dependent
45Ca2 uptake by Caco-2 cells.
Transcellular Ca2 transport in rabbit kidney CNT
and CCD primary cell cultures
Transcellular Ca2 transport was measured in primary
cultures of immunodissected rabbit kidney CNT and
CCD cells grown to confluency on permeable filter
supports. Application of 1  107 M 1,25(OH)2D3 for
48 h enhanced transcellular Ca2 absorption by the
confluent monolayers (Fig. 8B). Importantly, 1  107
M ZK191784 also stimulated Ca2 transport. Addition
of 1  107 M 1,25(OH)2D3 in the presence of 1  10
7
M ZK191784 did not result in a further enhancement of
transepithelial Ca2 transport.
Osteocalcin secretion in rat osteosarcoma cells
Ligand-induced osteocalcin production by ROS 17/2.8
cells was used to assess the potential of ZK191784 to
induce bone formation. Osteocalcin is produced by
mature osteoblasts at the onset of ECM production.
Both 1,25(OH)2D3 and ZK191784 induced osteocalcin
production in a dose-dependent manner (Fig. 9). The
concentration for half maximal increase (EC50) was
2.3 
 1010 M for 1,25(OH)2D3 and 5.3 
 10
8 M for
ZK191784. The efficacy of ZK191784 compared with
1,25(OH)2D3 was 41%.
DISCUSSION
The present study demonstrated that ZK191784 acts as
an intestinal 1,25(OH)2D3 antagonist by diminishing
Figure 4. mRNA expression of renal Ca2 transporters during
treatment with ZK191784 in TRPV5/ and TRPV5/ mice.
Effect of ZK191784 treatment on renal mRNA expression of
the epithelial Ca2 channel TRPV5 (A) and the cytosolic
Ca2-binding protein calbindin-D28K (CaBP28K; B) was deter-
mined by real-time quantitative PCR analysis as ratio of HPRT
and depicted as percentage of TRPV5/ controls. Controls,
mice treated with vehicle only; ZK191784, mice treated for 28
days with the 1,25(OH)2D3 analog ZK191784 (50 g/kg/
day). Data are mean  se. *P 	 0.05 vs. TRPV5/ controls;
n  9 animals per group.
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1,25(OH)2D3-stimulated Ca
2 absorption. Studies in
TRPV5/ mice indicated that this action was achieved
by directly down-regulating intestinal Ca2 transport
protein expression. In contrast, in vivo and in vitro
experiments indicated that ZK191784 exerts partial
agonistic actions on Ca2 handling in kidney. This
tissue-specific partial 1,25(OH)2D3 agonism/antago-
nism reflects a biological profile unlike any other
1,25(OH)2D3 analog tested so far. Because ZK191784
does not stimulate intestinal Ca2 absorption, this
compound will be associated with less hypercalcemic
side effects compared with1,25(OH)2D3 and its analogs
currently used in clinical practice.
1,25(OH)2D3 is an important stimulatory hormone
of intestinal Ca2 absorption and is known to enhance
the expression of the duodenal Ca2 transporters (1).
TRPV5/ mice were previously shown to display hy-
pervitaminosis D due to the profound renal Ca2
wasting caused by abolishment of active Ca2 transport
in DCT and CNT (19). Indeed, these mice demon-
strated significantly enhanced duodenal TRPV6 and
calbindin-D9K expression and Ca
2 hyperabsorption.
Importantly, the 1,25(OH)2D3 analog ZK191784 nor-
malized the increased expression of the intestinal Ca2
transporters and, thereby, antagonized intestinal Ca2
hyperabsorption in TRPV5/ mice. Furthermore,
ZK191784 diminished Ca2 absorption in WT mice. In
contrast, previous studies from our laboratory demon-
strated that 1,25(OH)2D3 and several of its analogs
enhance Ca2 transporter expression and intestinal
Ca2 absorption in these mice (1, 27, 28). The fact that
duodenal Ca2 transporter expression was not signifi-
cantly altered in WT mice suggests that ZK191784
might also antagonize nongenomic effects of
1,25(OH)2D3 in the intestine. This finding is in line
with previous studies that suggested that when dietary
Ca2 content is sufficient, there is only limited genomic
1,25(OH)2D3-dependent stimulation of active Ca
2 ab-
sorption and, therefore, competitive binding of
ZK191784 to the nuclear VDR does not significantly
affect Ca2 transporter expression in these mice (28).
Taken together, these in vivo data indicated that
ZK191784 specifically inhibits 1,25(OH)2D3-stimulated
intestinal Ca2 absorption. To test this hypothesis in
vitro, we used the intestine-derived Caco-2 cell line,
which was previously shown to express both TRPV6 and
calbindin-D9K (26). These experiments showed that in
the absence of 1,25(OH)2D3, ZK191784 does not affect
Ca2 uptake by these cells. However, applied in com-
bination with 1,25(OH)2D3, ZK191784 was able to
significantly diminish 1,25(OH)2D3-stimulated Ca
2
uptake. Thus, the present data demonstrated that
ZK191784, unlike 1,25(OH)2D3, does not stimulate
Ca2 uptake by the intestine and exerts a unique
antagonistic effect on 1,25(OH)2D3-stimulated active
Ca2 absorption. This can explain why ZK191784 pos-
sesses reduced hypercalcemic potency, when adminis-
tered in a dose known to exert immunosuppressive
effects in vivo (3).
ZK191784 reduced renal Ca2 excretion and signifi-
cantly enhanced the expression levels of TRPV5 and
calbindin-D28K in WT mice. These proteins are tightly
regulated by 1,25(OH)2D3 and are crucial for renal
Ca2 reabsorption, which is exemplified by the robust
hypercalciuria in TRPV5/ mice (1, 19). Therefore,
the concomitantly increased Ca2 transporter expres-
sion and reduced Ca2 excretion in WT mice suggested
that ZK191784 exerts a 1,25(OH)2D3-agonistic action
on renal active Ca2 reabsorption. The stimulatory
effect of ZK191784 on transcellular Ca2 transport in
primary cultures of rabbit CNT and CCD substantiated
these findings. Interestingly, ZK191784 did not increase
Figure 5. Protein abundance of renal Ca2 transporters during treatment with ZK191784 in TRPV5/ and TRPV5/ mice.
Representative immunohistochemical images of TRPV5 (A) and calbindin-D28K (CaBP28K; B) staining in kidney cortex.
Semiquantification of renal TRPV5 (C) and calbindin-D28K (D) protein abundance was performed by computerized analysis of
immunohistochemical images. Data were calculated as IOD (arbitrary units) and depicted as percentage of TRPV5/ controls.
Controls, mice treated with vehicle only; ZK191784, mice treated for 28 d with the 1,25(OH)2D3 analog ZK191784 (50
g/kg/day). Data are mean  se. *P 	 0.05 vs. TRPV5/ controls; n  9 animals per group.
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calbindin-D28K abundance in TRPV5
/ mice. How-
ever, previous studies from our group demonstrated
that blockade of TRPV5-mediated Ca2 influx in DCT
and CNT cells down-regulates calbindin-D28K expres-
sion (29). This indicated that regulation of the latter
protein is highly dependent on the magnitude of the
Ca2 influx through TRPV5. This could explain the
significantly reduced calbindin-D28K expression in
TRPV5/ mice, despite elevated 1,25(OH)2D3 levels
(19), as well as the absence of a stimulatory effect of
ZK191784 in these mice. Interestingly, ZK191784 still
resulted in a Ca2-sparing action in TRPV5/ mice
that, obviously, cannot be explained by stimulation of
active Ca2 reabsorption. The unaffected Li clearance
compared with controls, as an inverse measure of
proximal tubular Na reabsorption to which passive
Ca2 reabsorption is functionally coupled, does also
not support enhanced proximal tubular Ca2 reabsorp-
tion. However, abolishment of the compensatory intes-
tinal Ca2 hyperabsorption and reduced serum Ca2
levels will likely result in a decreased filtered Ca2 load
and, therefore, would be in line with the decreased
Ca2 excretion. Likewise, the fact that ZK191784 had
only a small effect on Ca2 excretion in TRPV5/
mice demonstrated that the 1,25(OH)2D3-mediated
Ca2 hyperabsorption does not contribute largely to
the hypercalciuria. Together, these findings underline
the presence of a primary renal Ca2 leak in TRPV5/
mice.
The expression of TRPV5 and TRPV6 in bone was
previously demonstrated, but the functional role of
these epithelial Ca2 channels in this tissue remained
unknown (18). In the present study, we showed that
TRPV5/ mice display unaltered bone TRPV6 expres-
sion, suggesting that TRPV6 does not compensate for
the absence of TRPV5. This argues against redundancy
of epithelial Ca2 channels in bone and indicates that
both channels play distinct roles in bone Ca2 ho-
meostasis. Recently, the exclusive expression of TRPV5
in the ruffled border of osteoclasts in bone was dem-
onstrated (17). Furthermore, cultured osteoclasts from
TRPV5/ mice displayed reduced bone resorptive
capacity, suggesting that this channel is involved in
osteoclastic bone resorption. However, ZK191784 did
not alter TRPV5 expression in WT mice but increased
bone TRPV6 expression in both mice strains. Ligand-
induced osteocalcin production by ROS 17/2.8 cells
Figure 6. mRNA expression of epithelial Ca2 channels in
bone during treatment with ZK191784 in TRPV5/ and
TRPV5/ mice. Effect of ZK191784 treatment on mRNA
expression of the epithelial Ca2 channels TRPV5 (A) and
TRPV6 (B) in bone was determined by real-time quantitative
PCR analysis as the ratio of HPRT and depicted as percentage
of TRPV5/ controls. Controls, mice treated with vehicle
only; ZK191784, mice treated for 28 days with the
1,25(OH)2D3 analog ZK191784 (50 g/kg/day). Data are
mean  se. *P 	 0.05 vs. TRPV5/ controls; #P 	 0.05 vs.
TRPV5/ controls; n  9 animals per group.
Figure 7. Bone morphometry after treatment
with ZK191784 in TRPV5/ and TRPV5/
mice. Representative cross-sectional X-ray im-
ages of the femoral head (a), lesser trochanter
(b), and diaphysis (c) in control and ZK191784-
treated TRPV5/ and TRPV5/ mice (A).
Three-dimensional reconstruction of femurs
from control and ZK191784-treated TRPV5/
and TRPV5/ mice (B). Controls, mice
treated with vehicle only; ZK191784, mice
treated for 28 days with the 1,25(OH)2D3 ana-
log ZK191784 (50 g/kg/day).
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was used to assess the bone formation properties of
ZK191784. Although rat osteosarcoma cells secreted
osteocalcin on treatment with 1,25(OH)2D3 as well as
ZK191784, the efficacy of the latter was rather weak.
Accordingly, detailed microcomputed tomography of
bone did not suggest a significantly altered bone turn-
Figure 8. Differential effect of 1,25(OH)2D3 and ZK191784
on 45Ca2 uptake in the intestinal Caco-2 cell line and on
transepithelial Ca2 transport in rabbit kidney CNT/CCD
primary cell cultures. 45Ca2 uptake was determined in
Caco-2 cells incubated for 48 h in normal culture medium
(Control), culture medium supplemented with 1  107 M
1,25(OH)2D3, 1  10
7 M ZK191784 or 1  107 M
1,25(OH)2D3 together with 1  10
7 M ZK191784, respectively
(A). Data are depicted as ruthenium red (RR)-sensitive
uptake. Transcellular Ca2 transport was determined in im-
munodissected rabbit CNT/CCD cultures incubated for 48 h
in normal culture medium (Control), culture medium sup-
plemented with 1  107 M 1,25(OH)2D3, 1  10
7 M
ZK191784 or 1  107 M 1,25(OH)2D3 together with 1  10
7
M ZK191784 (B). Data are mean se. *P	 0.05 vs. untreated
cells (Control). #P 	 0.05 vs. 1,25(OH)2D3-treated cells.
Figure 9. Effect of 1,25(OH)2D3 and ZK191784 on osteocal-
cin production in a rat osteosarcoma cell line. Ligand-
induced osteocalcin production was determined in ROS
17/2.8 cells stimulated for 72 h with increasing concentra-
tions of 1,25(OH)2D3 (Œ) or ZK191784 (f) to obtain a
dose-response curve (B).
TABLE 2. Bone analysis during ZK191784 treatment in TRPV5/ and TRPV5/ mice
TRPV5/ TRPV5/
Controls ZK191784 Controls ZK191784
Femoral head
Tb.Th ( m) 84.4  2.1 82.0  2.8 76.7  1.1* 79.4  1.8
BV/TV (%) 0.22  0.01 0.21  0.01 0.21  0.01 0.20  0.01
CD/TV (mm3) 81  11 112  28 117  15 90  14
Metaphysis
Ct.Th (m) 299  12 300  7 255  10* 271  8†
Ct.V (mm3) 1.9  0.1 1.9  0.1 1.7  0.1 1.7  0.1†
Ec.V (mm3) 3.2  0.1 3.4  0.1 3.5  0.1 3.2  0.1
Dp.V (mm3) 5.1  0.2 5.3  0.2 5.2  0.2 4.9  0.2
Ct.V/Dp.V 36.7  0.5 36.3  0.6 33.2  0.8 34.8  0.5
Diaphysis
Ct.Th (m) 292  6 290  7 247  10* 256  6†
Ct.V (mm3) 1.8  0.1 1.8  0.1 1.7  0.1 1.7  0.1
Ec.V (mm3) 3.0  0.2 3.0  0.1 3.1  0.1 3.0  0.1
Dp.V (mm3) 4.8  0.3 4.8  0.1 4.8  0.2 4.6  0.1
Ct.V/Dp.V 36.9  0.4 37.7  0.4 35.9  0.8 36.1  0.3
Controls, mice treated with vehicle only; ZK191784, mice treated for 28 days with 1,25(OH)2D3 analog ZK191784 (50 g/kg/day). In
femoral head, bone volume (BV), total bone marrow volume including trabeculae (TV), trabecular bone volume fraction (BV/TV), trabecular
thickness (Tb.Th), and connectivity density (CD/TV) (measure of interconnectivity of trabecular network) were determined. In metaphysis and
diaphysis, calculations were performed with regard to cortical thickness (Ct.Th), cortical volume (Ct.V), endocortical volume (Ec.V), total
diaphyseal volume (Dp.V) (sum of Ct.V and Ec.V), and cortical bone volume fraction (Ct.V/Dp.V). Data are mean se. *P	 0.05 vs. TRPV5/
controls; †P 	 0.05 vs. ZK191784-treated TRPV5/.
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over in ZK191784-treated mice. On the other hand, we
cannot exclude that prolonged ZK191784 administra-
tion will affect bone mineral density. In addition,
morphometric analysis showed that trabecular and
cortical thickness was reduced in TRPV5/ mice. The
exact explanation for this bone phenotype remains
elusive but in addition to a primary defect due to
TRPV5 ablation could be a consequence of the negative
Ca2 balance or a direct result of the hypervitaminosis
D. When administered chronically in supraphysiologi-
cal concentrations, 1,25(OH)2D3 was previously shown
to reduce cortical bone thickness (30).
In summary, this study demonstrated that ZK191784
acts as an intestine-specific 1,25(OH)2D3 antagonist.
Similar tissue-specific effects have been described for
e.g., the partial estrogen receptor agonist tamoxifen,
which was shown to exert a breast-selective, bone-
sparing antagonistic action (31–34). Furthermore, our
results in TRPV5/ mice suggest that ZK191784 may
ameliorate the clinical picture in disorders that are
characterized by high 1,25(OH)2D3 levels or intestinal
Ca2 hyperabsorption. Taken together, the unique
properties of this new 1,25(OH)2D3 analog might be of
great benefit in clinical practice, where complete inhi-
bition or stimulation, of the 1,25(OH)2D3 endocrine
system is mostly undesirable.
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SPECIFIC AIMS
The main physiological function of vitamin D3
[1,25(OH)2D3] is to stimulate intestinal and renal Ca
2
(re)absorption and regulate bone Ca2 turnover. In
addition, 1,25(OH)2D3 has potent antiproliferative,
immunosuppressive, and immunomodulatory activity.
However, therapeutic administration of 1,25(OH)2D3
has dose-limiting hypercalcemic side effects. Therefore,
there has been great effort in identifying new
1,25(OH)2D3 analogs that retain a beneficial therapeu-
tic profile with minimal calcemic action. The
1,25(OH)2D3 analog ZK191784 was developed in an
effort to dissociate the immunomodulatory and hyper-
calcemic actions of 1,25(OH)2D3. However, the in vivo
effects of ZK191784 regarding Ca2 homeostasis have
not been evaluated in detail.
1,25(OH)2D3-stimulated transcellular Ca
2 (re)ab-
sorption involves Ca2 entry across the luminal mem-
brane via the epithelial Ca2 channels TRPV5 and
TRPV6. TRPV5 is localized at the luminal membrane of
the late distal convoluted tubule (DCT) and connect-
ing tubule (CNT) in kidney. TRPV6 is the homologous
epithelial Ca2 channel localized along the brush-
border membrane of duodenum. TRPV5 knockout
(TRPV5/) mice display profound renal Ca2 wasting
due to impaired active Ca2 reabsorption in DCT and
CNT. Furthermore, these mice show hypervitaminosis
D leading to intestinal Ca2 hyperabsorption and dis-
play reduced bone thickness.
The aim of this study was, therefore, to evaluate the
effect of ZK191784 on Ca2 absorption, Ca2 excretion
and expression of the Ca2 transport proteins in intes-
tine and kidney in wild-type (WT) and TRPV5/ mice.
Furthermore, the actions of ZK191784 on intestinal,
renal, and osteosarcoma cell lines were characterized to
reveal the biological profile of this novel 1,25(OH)2D3
analog.
PRINCIPAL FINDINGS
1. Metabolic studies in ZK191784-treated WT and
TRPV5/ mice
WT and TRPV5/ mice were treated for 28 days with
50 g/kg/day ZK191784 or vehicle by daily subcutane-
ous injection. Genetic ablation of TRPV5 resulted in a
10-fold increase in Ca2 excretion compared with WT
mice (Fig. 1A) and enhancement of intestinal Ca2
absorption as determined by in vivo 45Ca2 absorption
measurements (Fig. 1B), accompanied by a minor
increase in the serum Ca2 concentration. ZK191784
treatment in TRPV5/ mice normalized the intestinal
Ca2 hyperabsorption as well as the serum Ca2 con-
centration. In addition, Ca2 excretion was decreased
by ZK191784 administration in TRPV5/ mice but
remained significantly elevated compared with WT
mice (Fig. 1A). Furthermore, ZK191784 treatment sig-
nificantly diminished intestinal Ca2 absorption and
decreased Ca2 excretion in WT mice, (Fig. 1B) with-
out altering serum Ca2 levels.
2. ZK191784 inhibits 1,25(OH)2D3-stimulated Ca
2
absorption and intestinal Ca2 transporter expression
To study the in vivo effect of ZK191784 on the abun-
dance of Ca2 transporters in the intestine, TRPV6 and
calbindin-D9K mRNA expression was determined by
real-time quantitative polymerase chain reaction (PCR)
analysis. TRPV5/ mice showed profoundly increased
TRPV6 and calbindin-D9K mRNA levels in duodenum
compared with WT mice. ZK191784 significantly re-
duced the TRPV6 and calbindin-D9K mRNA abundance
in TRPV5/ mice, resulting in a complete normaliza-
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tion of the expression of the intestinal Ca2 transport-
ers.
To determine the effect of ZK191784 in an intestinal
cell model, 45Ca2 uptake was determined in the
human Caco-2 cell line. Application of 1  107 M
1,25(OH)2D3 for 48 h enhanced the ruthenium red-
sensitive 45Ca2 uptake, substantiating the presence of
1,25(OH)2D3-responsive and TRPV6-mediated Ca
2
absorption in these polarized epithelial intestinal cells
(Fig. 2A). In contrast, incubation with 1  107 M
ZK191784 did not stimulate 45Ca2 uptake. Impor-
tantly, concomitant application of 1  107 M ZK191784
and 1  107 M 1,25(OH)2D3 significantly inhibited the
1,25(OH)2D3-dependent
45Ca2 uptake by Caco-2 cells.
3. ZK191784 up-regulates renal Ca2 transport
proteins and stimulates transcellular Ca2
reabsorption
To evaluate the effect of ZK191784 on the expression of
the Ca2 transport proteins in the kidney, TRPV5 and
calbindin-D28K mRNA as well as protein abundance
were determined by real-time quantitative PCR and
semiquantitative immunohistochemistry, respectively.
ZK191784 significantly increased TRPV5 and calbindin-
D28K mRNA levels and enhanced protein abundance of
these Ca2 transporters in DCT and CNT of WT mice.
Transcellular Ca2 transport was measured in pri-
mary cultures of immunodissected rabbit kidney CNT
and cortical collecting duct (CCD) cells grown to
confluency on permeable filter supports. Application of
1  107 M 1,25(OH)2D3 for 48 h enhanced transcellu-
lar Ca2 absorption by the confluent monolayers (Fig.
2B). Importantly, 1  107 M ZK191784 also stimulated
Ca2 transport. Addition of 1  107 M 1,25(OH)2D3 in
the presence of 1  107 M ZK191784 did not result in
a further enhancement of transepithelial Ca2 trans-
port.
4. Effects of ZK191784 on bone
Bone TRPV5 mRNA levels were not affected by
ZK191784 in WT mice, but TRPV6 mRNA expression
was significantly enhanced in ZK191784-treated WT
and TRPV5/ mice. Ligand-induced osteocalcin pro-
duction by reactive oxygen species (ROS) 17/2.8 cells
was used to assess the potential of ZK191784 to induce
bone formation. Osteocalcin is produced by mature
osteoblasts at the onset of extracellular matrix produc-
tion. Both 1,25(OH)2D3 and ZK191784 induced osteo-
calcin production in a dose-dependent manner.
To evaluate the in vivo effects of ZK191784 on bone
morphology, femurs from control and ZK191784-
treated mice were scanned using microcomputed to-
mography. Detailed three-dimensional morphometric
analysis demonstrated that both trabecular and cortical
Figure 2. Differential effect of 1,25(OH)2D3 and ZK191784
on 45Ca2 uptake in the intestinal Caco-2 cell line and on
transepithelial Ca2 transport in rabbit kidney CNT/CCD
primary cell cultures. 45Ca2 uptake was determined in
Caco-2 cells incubated for 48 h in normal culture medium
(Control) or culture medium supplemented with 1  107 M
1,25(OH)2D3, 1  10
7 M ZK191784 or 1  107 M
1,25(OH)2D3 together with 1  10
7 M ZK191784, respectively
(A). Data are depicted as ruthenium red (RR)-sensitive
uptake. Transcellular Ca2 transport was determined in im-
munodissected rabbit CNT/CCD cultures incubated for 48 h
in normal culture medium (Control), culture medium sup-
plemented with 1  107 M 1,25(OH)2D3, 1  10
7 M
ZK191784, or 1  107 M 1,25(OH)2D3 together with 1  10
7
M ZK191784 (B). Data are mean se. *P 0.05 vs. untreated
cells (Control); #P  0.05 vs. 1,25(OH)2D3-treated cells.
Figure 1. Renal Ca2 excretion and intestinal Ca2 absorp-
tion during treatment with ZK191784 in TRPV5/ and
TRPV5/ mice. Effect of ZK191784 on renal Ca2 excretion
was determined in metabolic cages (A). Intestinal Ca2
absorption was determined in an in vivo 45Ca2 absorption
assay, measuring serum 45Ca2 at early time points after oral
gavage (B). Controls, mice treated with vehicle only;
ZK191784, mice treated for 28 days with the 1,25(OH)2D3
analog ZK191784 (50 g/kg/day).   TRPV5/ controls,
treated with vehicle only; f  ZK191784-treated TRPV5/;
‚  TRPV5/ controls, treated with vehicle only; Œ 
ZK191784-treated TRPV5/. Data are mean  se. *P  0.05
vs. TRPV5/ controls; #P 0.05 vs. TRPV5/ controls; n
9 animals per group.
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thickness are reduced in TRPV5/ mice. ZK191784
did not significantly affect bone morphometric param-
eters in both mice strains nor were there differences in
the other trabecular and cortical bone parameters
between the treated groups.
CONCLUSIONS AND SIGNIFICANCE
The present study demonstrated that ZK191784 acts as
an intestinal 1,25(OH)2D3 antagonist by diminishing
1,25(OH)2D3-stimulated Ca
2 absorption. Studies in
TRPV5/ mice indicated that this action was achieved
by directly down-regulating intestinal Ca2 transport
protein expression. In contrast, ZK191784 exerted par-
tial agonistic actions on Ca2 handling in kidney and
bone. This tissue-specific partial 1,25(OH)2D3 ago-
nism/antagonism reflects a biological profile unlike
any other 1,25(OH)2D3 analog used so far (Fig. 3).
ZK191784 normalized the increased expression of
the intestinal Ca2 transporters and, thereby, antago-
nized the Ca2 hyperabsorption in TRPV5/ mice.
Previous studies from our laboratory demonstrated that
1,25(OH)2D3 and several analogs enhance Ca
2 trans-
porter expression and intestinal Ca2 absorption. Fur-
thermore, ZK191784 diminished Ca2 absorption in
WT mice. These data indicated that ZK191784 specifi-
cally inhibits 1,25(OH)2D3-stimulated intestinal Ca
2
absorption. To test this hypothesis in vitro, we used the
intestine-derived Caco-2 cell line, which expresses
TRPV6 and calbindin-D9K. In the absence of
1,25(OH)2D3, ZK191784 did not affect Ca
2 uptake by
these cells. However, applied in combination with
1,25(OH)2D3, ZK191784 was able to significantly di-
minish 1,25(OH)2D3-stimulated Ca
2 uptake. Thus,
unlike 1,25(OH)2D3, ZK191784 does not stimulate
Ca2 uptake by the intestine and exerts a unique
antagonistic effect on 1,25(OH)2D3-stimulated active
Ca2 absorption.
Renal Ca2 transporter expression is tightly regu-
lated by 1,25(OH)2D3. The concomitantly increased
renal TRPV5 and calbindin-D28K expression accompa-
nied by reduced Ca2 excretion in WT mice suggested
that ZK191784 exerts a 1,25(OH)2D3-agonistic action
on renal active Ca2 reabsorption. The stimulatory
effect of ZK191784 on transcellular Ca2 transport in
primary cultures of rabbit CNT and CCD substantiated
the in vivo findings. Interestingly, ZK191784 did not
increase calbindin-D28K abundance in TRPV5
/ mice.
Previous studies from our group demonstrated that
calbindin-D28K expression is highly dependent on the
TRPV5-mediated Ca2 influx in DCT and CNT cells.
This could explain the significantly reduced calbindin-
D28K expression in TRPV5
/ mice, despite elevated
1,25(OH)2D3 levels, and the absence of a stimulatory
effect of ZK191784 in these mice. ZK191784 still re-
sulted in a Ca2-sparing action in TRPV5/ mice that,
obviously, cannot be explained by stimulation of active
Ca2 reabsorption. However, abolishment of Ca2 hy-
perabsorption and reduced serum Ca2 results in a
decreased filtered Ca2 load and, therefore, dimin-
ished Ca2 excretion.
The functional role of TRPV5 and TRPV6 in bone
remains largely elusive. Recently, it was demonstrated
that TRPV5 is exclusively expressed in the ruffled
border of osteoclasts and that cultured osteoclasts from
TRPV5/ mice display reduced bone resorptive capac-
ity. ZK191784 did not alter TRPV5 expression but
increased bone TRPV6 expression. Ligand-induced os-
teocalcin production by ROS 17/2.8 cells was used to
assess the bone formation properties of ZK191784.
Although rat osteosarcoma cells secreted osteocalcin
on treatment with 1,25(OH)2D3 and ZK191784, the
efficacy of the latter was rather weak. Bone morphom-
etry did not suggest altered bone turnover in
ZK191784-treated mice.
In conclusion, this study demonstrated that ZK191784
is an intestine-specific 1,25(OH)2D3 antagonist, being
one of few synthetic 1,25(OH)2D3 ligand displaying
tissue-specific effects in vivo. These unique properties
might be of benefit in clinical practice where complete
inhibition, or stimulation, of the 1,25(OH)2D3 endo-
crine system is mostly undesirable. Our results indicate
this compound will display reduced hypercalcemic po-
tential compared with 1,25(OH)2D3 and its analogs
currently used in clinical practice.
Figure 3. Schematic representation of the differential tissue-
specific effects of ZK191784 compared with 1,25(OH)2D3
regarding Ca2 homeostasis and expression of Ca2 trans-
porters. ZK191784 inhibits 1,25(OH)2D3-stimulated Ca
2 ab-
sorption in vivo and in the intestinal Caco-2 cell line and
down-regulates 1,25(OH)2D3-stimulated intestinal Ca
2
transporter expression. ZK191784 and 1,25(OH)2D3 both
display stimulatory effects in vivo on Ca2 reabsorption and
renal Ca2 transporter expression as well as in primary
cultures of immunodissected rabbit kidney CNT and CCD
cells. Furthermore, ZK191784 and 1,25(OH)2D3 stimulate
osteocalcin secretion by ROS17/2.8 cells.
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